Rexahn appoints Richard Rodgers to board
This article was originally published in Scrip
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer, has appointed Richard Rodgers to its board of directors. Mr Rodgers was most recently executive vice-president, chief financial officer, secretary and treasurer of Tesaro, an oncology focused biopharmaceutical company which he co-founded. He also serves as a director for Ardelyx.